New Episode!
We’re breaking down the biggest #MBC updates from #SABCS2025 with Dr. Bora Lim of
@mdanderson.bsky.social. What does the latest research actually mean for patients right now? Tune in to find out.
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#MBC #BCSM #CanSky #podcast

New Season Starts Wednesday!
Join us as we break down some of the biggest metastatic breast cancer updates from the 2025 San Antonio Breast Cancer Symposium with Dr. Bora Lim of @mdanderson.bsky.social. Stay tuned!
#MBCResearch #SABCS2025 #OMBCL #BCSM #CanSky #podcast

The FDA has removed the black box warning from most menopause hormone therapy (HRT) drugs, raising new questions about safety. Experts at #SABCS2025 discussed what this may mean for people with #breastcancer. Learn more: https://bit.ly/4cm6e9b

Want the five key themes shaping the future of breast cancer care? Check out our perspective from the San Antonio Breast Cancer Symposium (SABCS) 2025.

Read the insights, data highlights, and actionable recommendations: lumanity.com?post_type=pe....

#SABCS2025 #BreastCancer #Patients

Adding alpelisib to fulvestrant improves PFS and OS in patients with PIK3CA-mut, HR+, HER2− advanced #breastcancer who had progressed on a CDK4/6 inhibitor and aromatase inhibitor. Presented at @sabcs.bsky.social #SABCS25.

https://bit.ly/4qKWOrH

#bcsm #SABCS2025

There's still time to register for our upcoming #webinar! Dr. Bora Lim, breast oncologist with
@mdanderson.bsky.social, shares important information on clinical trial outcomes shared at #SABCS2025.
Register here: buff.ly/FwfjwJy
#ClinicalTrials #MBC #BCSM #CanSky

High-Dose Preoperative RT Plus ICI Stimulates T-Cell Infiltration in HR+, HER2- EBC - Oncology Nurse Advisor This phase 2 trial explored whether preoperative RT combined with an immune checkpoint inhibitor may act as an immune stimulator, enhancing T-cell infiltration.

High-dose preoperative radiotherapy plus pembrolizumab increased T-cell infiltration in node-positive, higher-risk, HR-positive, HER2-negative early #breastcancer. Presented at the @sabcs.bsky.social #SABCS25, covered by @cancertherapyadv.bsky.social.

https://bit.ly/4qHawMh

#bcsm #SABCS2025

Join us for our upcoming #webinar! Dr. Bora Lim, breast oncologist with @mdanderson.bsky.social, shares important information on clinical trial outcomes shared at #SABCS2025.
Register here: buff.ly/FwfjwJy
#ClinicalTrials #MBC #BCSM #CanSky

@sabcs.bsky.social #SABCS2025 highlighted research of #bcsm. Our most popular articles include:

🥦 Eating Cruciferous Vegetables May Reduce #BreastCancer Risk: https://bit.ly/4pzZasM Research from @andrearomanosphd.bsky.social of @harvardmed.bsky.social.

Read more here: ➡️https://bit.ly/4ju11Oe

Dana-Farber Researchers Present Over 50 Studies and Receive Honors at SABCS 2025 - OncoDaily Dana-Farber Researchers Present Over 50 Studies and Receive Honors at SABCS 2025 / American Association for Cancer Research, cancer, Dana-Farber Cancer

Dana-Farber Researchers Present Over 50 Studies and Receive Honors at SABCS 2025

@danafarber.bsky.social @danafarbernews.bsky.social @sabcs.bsky.social

oncodaily.com/voices/dana-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DanaFarber #SABCS #SABCS25 #SABCS2025

Still curious about #SABCS2025? Sign up to read our exclusive recap of the meeting, with insights from leading breast cancer experts! @erikahamilton9.bsky.social @elmayermd.bsky.social @uclahealth.org @danafarber.bsky.social @sabcs.bsky.social #bcsm #oncology
www.onclive.com/view/experts...

UTMB SPPH faculty spotlight: Dr. Lisa Campo-Engelstein presented at #SABCS2025 on ethical issues in caring for young breast cancer patients, including patient-centered decision-making and access to fertility preservation options. She also delivered two invited talks at UT San Antonio.

Recap from the 48th Annual San Antonio Breast Cancer Symposium - Yale Cancer Center - OncoDaily Recap from the 48th Annual San Antonio Breast Cancer Symposium - Yale Cancer Center / cancer, Eric Winer, Lajos Pusztai, Maryam Lustberg, OncoDaily, Oncology,

Yale Cancer Center - Recap from the 48th Annual San Antonio Breast Cancer Symposium

@yalecancer.bsky.social @sabcs.bsky.social

oncodaily.com/voices/san-a...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025

Maryam Lustberg: A Jam-Packed SABCS25 Filled with New Learning, Collaborations, and Friendship - OncoDaily Maryam Lustberg: A Jam-Packed SABCS25 Filled with New Learning, Collaborations, and Friendship / cancer, Maryam Lustberg, OncoDaily, Oncology, SABCS, SABCS

A Jam-Packed SABCS25 Filled with New Learning, Collaborations, and Friendship - Maryam Lustberg

@maryamlustberg.bsky.social @sabcs.bsky.social

oncodaily.com/voices/marya...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025

EMBER-3 Trial: Imlunestrant in ER+/HER2− Breast Cancer At SABCS 2025, updated EMBER-3 trial data demonstrate durable efficacy and survival trends with imlunestrant in ER+/HER2− aBC

EMBER-3 at SABCS: Updated OS and PFS With Imlunestrant ± Abemaciclib

@sabcs.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EMBER-3 #SABCS #SABCS25 #SABCS2025

25 Posts Not to Miss from SABCS 2025 - OncoDaily 25 Posts Not to Miss from SABCS 2025 / Abi Siva, Aydah AlAwadhi, cancer, Daniel Stover, Erika Hamilton, Francisco J. Esteva, Gaia Griguolo, Harold J.

25 Posts Not to Miss from SABCS 2025

@sabcs.bsky.social

oncodaily.com/not-to-miss/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025

RAD51-Based HRD Test Could Help Refine Patient Selection for Olaparib in BRCA1/2- or PALB2-Mutant, HER2– Breast Cancer | OncLive RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

RAD51-Based HRD Test Could Help Refine Patient Selection for Olaparib in BRCA1/2- or PALB2-Mutant, HER2– Breast Cancer #SABCS2025 #bcsm #oncology www.onclive.com/view/rad51-b...

20 Posts Not to Miss from SABCS 2025, Part 2 - OncoDaily 20 Posts Not to Miss from SABCS 2025, Part 2 / Alexis LeVee, Armando Orlandi, Aydah AlAwadhi, cancer, Erika Hamilton, Gaia Griguolo, Headlines, Hope Rugo,

20 Posts Not to Miss from SABCS 2025, Part 2

@sabcs.bsky.social

oncodaily.com/not-to-miss/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025

SABCS 2025: Endocrine Therapy in HR+ MBC SABCS 2025 highlights major advances in HR-positive metastatic breast cancer endocrine therapy, including oral SERDs, targeted combinations.

SABCS 2025: A New Framework for Endocrine Therapy in HR+/HER2– Metastatic Breast Cancer

@sabcs.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025

Inside SABCS 2025 with Paolo Tarantino - OncoDaily Inside SABCS 2025 with Paolo Tarantino / cancer, Headlines, OncoDaily, Oncology, Paolo Tarantino, SABCS, SABCS 2025, SABCS2025, SABCS25, San Antonio Breast

Inside SABCS 2025 with Paolo Tarantino

@sabcs.bsky.social @ptarantinomd.bsky.social

oncodaily.com/voices/sabcs...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SABCS #SABCS25 #SABCS2025

Risk-Based Screening Works as Well as Yearly Checks After 40 in Finding Breast Cancers

"Probably the most important study that’s been presented at this meeting.” Dr. Eric Winer of @yalecancer.bsky.social comments on results from @wisdomstudy.bsky.social by lead author Dr. Laura Esserman @ucsfhealth.bsky.social at #SABCS2025 @sabcs.bsky.social www.nytimes.com/2025/12/12/h...

SABCS25: Agendia’s genomic testing guides breast cancer care  Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.

New data from Agendia's FLEX study at #SABCS2025 shows genomic signatures like MammaPrint can guide chemo choices & identify benefit in elderly patients.
#news #breastcancer #precisionmedicine #realworldevidence

SABCS25: Agendia’s genomic testing guides breast cancer care  Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.

New data from Agendia's FLEX study at #SABCS2025 shows genomic signatures like MammaPrint can guide chemo choices & identify benefit in elderly patients.
#news #breastcancer #precisionmedicine #realworldevidence

L’estudi PremiÈRe, liderat per #SOLTI i presentat a #SABCS2025 per Meritxell Bellet, posiciona l'elacestrant com un fàrmac prometedor per al tractament del #CàncerDeMama en dones joves diagnosticades durant la premenopausal

➡️ https://linke.to/PremiereVHIO_Cat
@hospitalclinic.bsky.social | #MamaVHIO

El estudio PremiÈRe de #SOLTI, presentado en #SABCS2025 por Meritxell Bellet, posiciona elacestrant como un fármaco prometedor para tratamiento del #CáncerDeMama en mujeres jóvenes diagnosticadas durante la premenopausia. 
➡️ https://linke.to/PremiereVHIO_Cast
@hospitalclinic.bsky.social #MamaVHIO

Presented at #SABCS2025 by Meritxell Bellet results of the PremiÈRe study led by #SOLTI, which positions elacestrant as a promising drug for the treatment of breast cancer in young women diagnosed during premenopause.
➡️ https://linke.to/PremiereVHIO
@hospitalclinic.bsky.social | #MamaVHIO

Great job by all of my trainees and team at #SABCS2025!!

Honored to moderate the outstanding local therapy session! Three trials now coalesce around 8Gy x 3 to a small preop focus as an immune engaging dose in breast cancer. Exciting space to watch! Interesting radiation analyses from Insema too. #radoncsky #cansky #sabcs2025

Long-Term PALLAS Data Show No Adjusted OS Difference With Adjuvant Palbociclib in HR+/HER2– Breast Cancer | OncLive An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

Long-Term PALLAS Data Show No Adjusted OS Difference With Adjuvant Palbociclib in HR+/HER2– Breast Cancer #SABCS2025 #bcsm #oncology www.onclive.com/view/long-te...

🔍 #SABCS2025: #INSEMA Trial – #Radiotherapy Analysis (presented by Guido Hildebrandt)
Today’s presentation offered important insights into how radiotherapy was actually applied among patients undergoing breast-conserving surgery with or without sentinel lymph node biopsy #SLNB in the INSEMA trial.